FILE:MYL/MYL-8K-20101110171045.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
     On November 10, 2010, Mylan Inc. (the "Company") issued a press release announcing the final conversion rate applicable to its 6.50% Mandatory Convertible Preferred Stock (the "Preferred Stock") that will be converted into common stock of the Company effective as of November 15, 2010. The Company has determined that each share of Preferred Stock will be converted into 58.5480 shares of common stock. A copy of the press release is attached hereto as Exhibit 99.1.
     (d) Exhibits.
 
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

Exhibit 99.1
FOR IMMEDIATE RELEASE
CONTACTS: Michael Laffin (Media) 724.514.1968
Kris King (Investors) 724.514.1831
Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
 
PITTSBURGH  November 10, 2010  Mylan Inc. (Nasdaq: MYL) today announced that it has determined the final conversion rate applicable to its 6.50% Mandatory Convertible Preferred Stock (the "Preferred Stock") that will be converted into common stock of the company effective as of November 15, 2010. Mylan has determined that, in accordance with the governing provisions of the company's Amended and Restated Articles of Incorporation, as amended, each share of Preferred Stock will be converted at the close of business on November 15, 2010 into 58.5480 shares of common stock of the company, the minimum conversion ratio permitted by the Articles. This reflects the strong stock price performance of the company since the preferred stock was issued. Accordingly, an aggregate of 125,234,172 shares of common stock will be issued to record holders of Preferred Stock on November 15, 2010.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit .
www.mylan.com


